The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Lise Willems(Hôpital Cochin), Jérôme Tamburini(Centre National de la Recherche Scientifique), Dominique Bonnet(The Francis Crick Institute), Patrick Mayeux(Université Paris Cité), Olivier Hérault(Université de Tours), Sophie Park(Centre Hospitalier Universitaire de Grenoble), Aurélie Fricot(Inserm), Norbert Ifrah(Institut National du Cancer), Alexandre Puissant(Délégation Paris 5), Patrick Auberger(Inserm), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Thiago Trovati Maciel(Inserm), Nicolas Chapuis(Délégation Paris 5), Olivier Hermine(Centre National de la Recherche Scientifique), Didier Bouscary(Université Paris Cité), Nathalie Jacque(Institut Cochin), Christine Vignon(Université de Tours), I C Moura(Inserm), François Dreyfus(Université Paris-Sud), C. Lacombe(Délégation Paris 5), Alexa S. Green(Délégation Paris 5)
Cited by 161
Related Papers
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
|Oncogene|2008|852
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
|Cancer Research|2011|620
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543